This study will determine the effects of pregnenolone on brain function, inflammation and depressive symptoms in people with HIV who have depression. Participants in this study will receive a pill of either pregnenolone or placebo, and can stay on their current antidepression medications. Brain imaging and behavioral assessments will be performed during the study.

开始日期2023-03-03

申办/合作机构

The General Hospital Corp.

[+2]

NCT04793698 / RecruitingN/AIIT

Multisite Feasibility of Compassion Meditation for Veterans With Posttraumatic Stress Disorder (PTSD)

Compassion meditation (CM) is a contemplative practice that builds compassion for and connectedness with others. CM has shown promise as a way of enhancing recovery for Veterans with Posttraumatic Stress Disorder (PTSD). The proposed project will examine the feasibility of a clinical trial by assessing our ability to deliver CM and a control intervention consistently with a diverse groups of Veterans from different parts of the country and optimizing the way in which outcomes are determined.

开始日期2021-05-06

申办/合作机构

Emory University

[+3]

ISRCTN81915073 / CompletedN/A

Effectiveness of novel tools for integrated vector control management on the incidence of dengue in Malaysia: a cluster randomized controlled trial

开始日期2020-02-10

申办/合作机构

Institute for Medical Research, Inc.

100 项与 Institute for Medical Research, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Institute for Medical Research, Inc. 相关的专利（医药）

登录后查看更多信息

项与 Institute for Medical Research, Inc. 相关的文献（医药）

2025-01-01·Journal of Affective Disorders

Menopausal stage transitions and their associations with overall and individual sleep quality in middle-aged Korean women

Article

作者: Guallar, Eliseo ; Kim, Chanmin ; Hong, Yun Soo ; Park, Jihwan ; Cho, Juhee ; Park, Hyun-Young ; Kim, Kye-Hyun ; Park, Junhee ; Zhao, Di ; Lim, Ga-Young ; Chang, Yoosoo ; Jang, Yoonyoung ; Jeon, Sang Won ; Kang, Jeonggyu ; Ryu, Seungho ; Kim, Hoon ; Kwon, Ria

BACKGROUNDUnderstanding the association between the menopausal transition and declining sleep quality can guide optimal timing for preventive interventions in transitioning women. However, studies lack representation of Asian women and sufficient data on the progression of menopausal stages and sleep quality changes over time in this population.METHODSThis study included 3305 women in the pre-menopause stage at baseline. The sleep quality and its components were assessed using the Pittsburgh Sleep Quality Index (PSQI). Menopausal stages were classified as pre-menopause, early transition, late transition, and post-menopause according to the Stages of Reproductive Aging Workshop+10 (STRAW+10) criteria. We estimated the longitudinal association between menopausal stage changes over time and the PSQI score, and examined the effect of being overweight.RESULTSThe trends in the PSQI scores and its components according to the menopausal stage changes over time showed that with the exception of sleep duration and habitual sleep efficiency, an overall decline was noted in sleep health during late transition and post-menopause compared to pre-menopause. These associations were independent of time-variant annual chronological aging, which was not significantly associated with sleep deterioration. Additionally, although the associations between menopausal stages and sleep quality did not significantly differ by adiposity level, the overweight group exhibited worse PSQI scores and components than did the non-overweight group.LIMITATIONSleep quality and menopausal stage were assessed using self-reported questionnaires without objective measures.CONCLUSIONOur study underscores the importance of screening for sleep quality deterioration and implementing appropriate measures for women experiencing menopausal transition.

2024-12-31·International Journal of Hyperthermia

In vivo electrical properties of the healthy liver and the hepatic tumor in a mouse model between 1 Hz and 1 MHz during a thermal treatment

Article

作者: Song, Ruteng ; Li, Weichen ; Wang, Lei ; Zhu, Wenjing ; Wang, Weice ; Zhu, Mingxu ; Guo, Yitong ; Shi, Xuetao ; Li, Junyao ; Ji, Zhenyu

Objective: Understansding the changing patterns of in vivo electrical properties for the target tissue is crucial for the accurate temperature monitoring and the treatment efficacy in thermal therapy. Our research aims to investigate the changing patterns and the reversibility of in vivo electrical properties for both healthy livers and liver tumors in a mouse model over a frequency range of 1 Hz to 1 MHz at temperatures between 30 °C to 90 °C.Methods and materials: The mice were anesthetized and the target organ was exposed. An 808-nm near-infrared laser was employed as the heating source to heat the organ in vivo. The four-needle electrode, connected to an impedance analyzer, was utilized to obtain the impedance at varying temperatures, which were monitored by a thermocouple.Results: The findings indicated a gradual decline in impedance with an increase in temperature. Furthermore, the impedance was normalized to that at 30 °C, and the real part of the normalized impedance was defined as the k-values, which range from 0 to 1. The results demonstrated a linear correlation between k-values and temperatures (R² > 0.9 for livers and R² > 0.8 for tumors). Significant differences were observed between livers and tumors at 1, 10 and 50 kHz (p < 0.05). Additionally, it was demonstrated that the electrical properties could be reversed when the temperature was below or equal to 45 °C.Conclusion: We believe that these results will contribute to the advancement of radiofrequency ablation systems and the development of techniques for temperature monitoring during liver thermal treatment.

2024-09-01·Osteoarthritis and Cartilage Open

Reliability and agreement of manual and automated morphological radiographic hip measurements

Article

作者: Crossley, K. ; Ahedi, H. ; Nevitt, M C ; Runhaar, J. ; Arden, N K ; Arbabi, V. ; Jones, G. ; Kluzek, S ; Cicuttini, F M ; Weinans, H. ; Heerey, J ; Felson, D T ; Bierma-Zeinstra, S.M.A. ; Oei, E.H. ; Oei, E H ; Riedstra, N.S. ; Arbabi, V ; Agricola, R ; Arden, N.K. ; Lane, N.E. ; Tang, J ; van Buuren, M.M.A. ; Lynch, J. ; Lane, N E ; Hanff, D F ; Gielis, W.P. ; Boel, F. ; Weinans, H ; Nelson, A E ; Runhaar, J ; Eygendaal, D ; Heerey, J. ; Cicuttini, F.M. ; Mosler, A B ; van Meurs, J. ; Boel, F ; Mosler, A.B. ; Jones, G ; Cootes, T.F. ; Eygendaal, D. ; van Meurs, J ; Tang, J. ; Crossley, K ; Cootes, T F ; Nelson, A.E. ; Kluzek, S. ; Lindner, C ; Bierma-Zeinstra, S M A ; Felson, D.T. ; Riedstra, N S ; Lynch, J ; Ahedi, H ; van Buuren, M M A ; Lindner, C. ; Nevitt, M.C. ; Agricola, R. ; Hanff, D.F. ; Gielis, W P

ObjectiveTo determine the reliability and agreement of manual and automated morphological measurements, and agreement in morphological diagnoses.MethodsThirty pelvic radiographs were randomly selected from the World COACH consortium. Manual and automated measurements of acetabular depth-width ratio (ADR), modified acetabular index (mAI), alpha angle (AA), Wiberg center edge angle (WCEA), lateral center edge angle (LCEA), extrusion index (EI), neck-shaft angle (NSA), and triangular index ratio (TIR) were performed. Bland-Altman plots and intraclass correlation coefficients (ICCs) were used to test reliability. Agreement in diagnosing acetabular dysplasia, pincer and cam morphology by manual and automated measurements was assessed using percentage agreement. Visualizations of all measurements were scored by a radiologist.ResultsThe Bland-Altman plots showed no to small mean differences between automated and manual measurements for all measurements except for ADR. Intraobserver ICCs of manual measurements ranged from 0.26 (95%-CI 0-0.57) for TIR to 0.95 (95%-CI 0.87-0.98) for LCEA. Interobserver ICCs of manual measurements ranged from 0.43 (95%-CI 0.10-0.68) for AA to 0.95 (95%-CI 0.86-0.98) for LCEA. Intermethod ICCs ranged from 0.46 (95%-CI 0.12-0.70) for AA to 0.89 (95%-CI 0.78-0.94) for LCEA. Radiographic diagnostic agreement ranged from 47% to 100% for the manual observers and 63%-96% for the automated method as assessed by the radiologist.ConclusionThe automated algorithm performed equally well compared to manual measurement by trained observers, attesting to its reliability and efficiency in rapidly computing morphological measurements. This validated method can aid clinical practice and accelerate hip osteoarthritis research.

项与 Institute for Medical Research, Inc. 相关的新闻（医药）

2024-05-16

·PRNewswire

Mitsubishi Tanabe Pharma America Announces Presentations at XXIX World Congress on Parkinson's Disease and Related Disorders

JERSEY CITY, N.J., May 16, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced two presentations on investigational ND0612 in Parkinson's disease (PD) will be shared at the International Association of Parkinsonism and Related Disorders (IAPRD) XXIX World Congress on Parkinson's Disease and Related Disorders, being held in Lisbon, Portugal, May 19-22. "We are eager to discuss the latest findings from our ongoing Phase 3 BouNDless and Phase 2b BeyoND clinical trials evaluating the efficacy and safety of investigational ND0612 in people with Parkinson's disease experiencing motor fluctuations," said Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs, MTPA. "Our presence at IAPRD this year exemplifies our determination to continue exploring how to address the challenges faced by people living with this disease, including the impact of motor fluctuations." MTPA's posters will be presented during Oral Poster Sessions at the meeting on May 21, 2024 at 9:35 a.m. – 10:20 a.m. WEST. Presentation Details: Presentations include results from the pivotal Phase 3 multi-center, randomized, double-blind double-dummy BouNDless trial (NCT04006210) evaluating the efficacy, safety and tolerability of investigational ND0612 in people with PD experiencing motor fluctuations, in addition to three-year outcomes from the Phase 2b open-label BeyoND study (NCT02726386) evaluating the long-term safety of ND0612 in reducing OFF time in people with PD. Continuous subcutaneous levodopa/carbidopa infusion (ND0612) for patients with Parkinson's disease and motor fluctuations: A Phase 3, active-controlled BouNDless stud y (Fabrizio Stocchi, M.D., Ph.D., Institute for Research and Medical Care (IRCCS), San Raffaele, Rome) Oral Poster #O_42 Continuous subcutaneous levodopa/carbidopa infusion with ND0612 for Parkinson's disease: Three-year data from the open-label BeyoND study (Fabrizio Stocchi, M.D., Ph.D., University San Raffaele Roma and IRCCS San Raffaele) Oral Poster #O_41 About ND0612 ND0612 is an investigational drug-device combination therapy – a 24-hours/day, continuous subcutaneous (SC) infusion of liquid levodopa/carbidopa (LD/CD) for the treatment of motor fluctuations in people with Parkinson's disease (PD). Development of investigational ND0612 is being led by NeuroDerm, Ltd., a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC). About Mitsubishi Tanabe Pharma America, Inc. Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC). It was established by MTPC to develop and advance our pipeline as well as commercialize approved pharmaceutical products in North America. For more information, please visit or follow us on X (formerly Twitter), Facebook and LinkedIn. About Mitsubishi Tanabe Pharma Corporation Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi Chemical Group (MCG), is one of the oldest pharmaceutical companies in the world, founded in 1678. MTPC is headquartered in Doshomachi, Osaka, the birthplace of Japan's pharmaceutical industry. MCG has positioned health care as its strategic focus in its management policy, "Forging the future". MTPC sets the MISSION of "Creating hope for all facing illness". To that end, MTPC is working on the disease areas of central nervous system, immuno-inflammation, diabetes and kidney, and cancer. MTPC is focusing on "precision medicine" to provide drugs with high treatment satisfaction and additionally working to develop "around the pill solutions" to address specific patient concerns based on therapeutic medicine, including prevention of diseases, pre-symptomatic disease care, prevention of aggravation and prognosis. For more information, go to . About NeuroDerm, Ltd. NeuroDerm, Ltd. is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), based in Israel, inspired to reduce disease burden and improve the quality of life of patients and their families through innovative drug-device combination therapies and technologies. NeuroDerm is an integrated pharmaceutical and medical technology company developing central nervous system (CNS) product candidates. For additional information, please visit NeuroDerm's website at  or follow the Company on LinkedIn. Media inquiries: [email protected] SOURCE Mitsubishi Tanabe Pharma America

临床2期临床3期

2023-08-09

·Healthcare IT News

Ramsay Health Care scaling AI adoption with Google Cloud

Ramsay Health Care, one of Australia's largest private healthcare providers, is partnering with Google Cloud to acquire the capability to harmonise and harness data across its network to improve clinical and operational outcomes. Ramsay told Healthcare IT News that it chose Google Cloud as its data and innovation partner in fulfilling its 2030 digital transformation strategy. A key component of this strategy is the creation of a centralised data hub, which will be built using Google Cloud's enterprise data warehouse, BigQuery. The data hub, to be delivered in partnership with Google Cloud consultant Kasna, will allow Ramsay to safely ingest, store, and analyse both real-time data and diverse swaths of raw data. Patient data will be encrypted end-to-end through Google Cloud's infrastructure and data storage. Google Cloud will also be deploying the Apigee API Management and Anthos Service Mesh solutions to support data interoperability. WHY IT MATTERS Ramsay operates a network of more than 70 hospitals, clinics, and surgical centres across Australia. With healthcare service demand expected to rise gradually each year, the amount of data they hold is also projected to increase. However, its patient and administrative data are held in separate on-premise locations, "making analysis and insights extraction a time-intensive and cumbersome process," according to Dr Rachna Gandhi, chief digital and data officer of Ramsay Health Care. For this reason, Ramsay is building a centralised data hub, powered by Google Cloud, that will provide a single source of truth for all its data. This will allow the group to operationalise data, improve connectivity, and unlock new insights to support clinical decision-making. Aside from having better access to data and "significantly" improving data management, its partnership with Google Cloud will allow the organisation to use AI and ML tools, which have a "crucial role" in streamlining operational and clinical workflows, Dr Gandhi said. "For example, AI can reduce the administrative burden on clinicians and nurses, releasing further capacity to care for patients. AI will help doctors identify patients at risk of illness and our clinicians will also be able to use AI-powered tools to extract insights and enhance clinical decision-making by identifying patterns and trends that may not be obvious," she explained further. Ramsay Health Care is also looking to use AI to optimise clinical coding to improve accuracy, reducing the burden on medical coders. It will also explore the use of AI in forecasting demand to ensure medications will not go to waste and to enable a more systematic allocation of procedures for optimising theatre and staff utilisation. With Google Cloud, Ramsay is scaling its adoption of AI "without the need for purchasing additional hardware and devoting manpower towards building new systems." THE LARGER TREND Google Cloud has been actively supporting the digital transformations of health systems around Asia-Pacific. Early this year, it started working with Synapxe - formerly the Integrated Health Information Systems, in Singapore to scale the access to API gateway for developers to create new applications and capabilities for the healthcare system. Through Amwell, Google Cloud has recently powered the virtual and remote care capabilities of Manipal Hospitals in India. The healthcare group is also adopting its conversational AI tools to enhance patient interactions. Google Cloud has also helped process about 14,000 genomes – touted as the largest genome data set in Australia to date – with the Garvan Institute of Medical Research in Sydney to drive the early diagnosis of rare genetic disorders. Meanwhile, Ramsay is trying out this month a cloud-based platform that will provide patients and specialists with a single entry into its digital ecosystem. It will feature a pre-admission dashboard, digital consent capabilities, and payment systems. ON THE RECORD "We are on a significant journey to transform into a digitally enabled, data-informed integrated healthcare provider. As part of this transformation, we are excited to work with Google Cloud to unlock the maximum potential of data and AI and revolutionise the healthcare industry. We are committed to offering gold-standard clinical care while maintaining a responsible approach to data governance and privacy, and ensuring our customers retain control over their data," Dr Gandhi said about their partnership with Google Cloud.

2022-11-29

·Business Wire

Surgical Devices Pipeline Report, 2022 - Includes Stages of Development, Segments, Regions & Countries, Regulatory Path and Key Companies - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Surgical Devices Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive information about the Surgical Devices pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. Report Scope Extensive coverage of the Surgical Devices under development The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities The report reviews the major players involved in the development of Surgical Devices and list all their pipeline projects The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage The report provides key clinical trial data of ongoing trials specific to pipeline products Recent developments in the segment/industry The report enables you to: Formulate significant competitor information, analysis, and insights to improve R&D strategies Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage Identify and understand important and diverse types of Surgical Devices under development Develop market-entry and market expansion strategies Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline In-depth analysis of the product's current stage of development, territory and estimated launch date Key Topics Covered 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Surgical Devices Overview 3 Products under Development 3.1 Surgical Devices - Pipeline Products by Stage of Development 3.2 Surgical Devices - Pipeline Products by Segment 3.3 Surgical Devices - Pipeline Products by Territory 3.4 Surgical Devices - Pipeline Products by Regulatory Path 3.5 Surgical Devices - Pipeline Products by Estimated Approval Date 3.6 Surgical Devices - Ongoing Clinical Trials 4 Surgical Devices - Pipeline Products under Development by Companies 4.1 Surgical Devices Companies - Pipeline Products by Stage of Development 4.2 Surgical Devices - Pipeline Products by Stage of Development 5 Surgical Devices Companies and Product Overview 6 Surgical Devices - Recent Developments 7 Appendix 7.1 Methodology List of Tables Surgical Devices - Pipeline Products by Stage of Development Surgical Devices - Pipeline Products by Segment Surgical Devices - Pipeline Products by Territory Surgical Devices - Pipeline Products by Regulatory Path Surgical Devices - Pipeline Products by Estimated Approval Date Surgical Devices - Ongoing Clinical Trials Surgical Devices Companies - Pipeline Products by Stage of Development Surgical Devices - Pipeline Products by Stage of Development Glossary List of Figures Surgical Devices - Pipeline Products by Stage of Development Surgical Devices - Pipeline Products by Segment Surgical Devices - Pipeline Products by Territory Surgical Devices - Pipeline Products by Regulatory Path Surgical Devices - Pipeline Products by Estimated Approval Date Surgical Devices - Ongoing Clinical Trials Companies Mentioned 6S Medical LLC Abbott Operations Uruguay Srl Acoustic MedSystems Inc Aesculap Inc Anastom Surgical Anchora Medical Ltd Apercure Surgical Ltd Apollo Endosurgery Inc Applied Medical Resources Corporation Apyx Medical Corp Archon Medical Technologies LLC Augusta University Baxter International Inc BioTex Inc BriteSeed BTG International Inc Carnegie Mellon University Centre Hospitalier Universitaire de Nice Charite University Hospital of Berlin Chengdu Yurui Innovation Technology Co Ltd Colospan Ltd Control Medical Technology LLC Core Essence Orthopaedics, LLC Corporis Medical Covidien Ltd CR Bard Inc Creative Balloons GmbH Cryofocus Medtech Shanghai Co Ltd CT Resources Inc Cutera Inc Cypris Medical, Inc. Dartmouth College Deep Blue Medical Advances Inc Drexel University Emblation Ltd Embricon Ltd (Inactive) Endo Tools Therapeutics SA EndoEvolution, LLC Ethicon Endo-Surgery Inc ExpandoHeat LLC Fixit Medical Ltd Fogless International AB G.I. Windows Inc Galil Medical Ltd Garantis Genicon Inc GI Windows Medical Corp Grand Valley State University H. Lee Moffitt Cancer Center & Research Institute Inc Hangzhou Kangsheng Medical Equipment Co Ltd Hannover Medical School Harvard University Hospital for Special Surgery IceCure Medical Ltd Imperial College London Indian Institute of Technology Delhi Innovex Medical Co Ltd Integra LifeSciences Holdings Corp Intuitive Surgical Inc IonMed Ltd. Jinan Micro Intelligent Technology Co Ltd Johns Hopkins University Keren Medical Ltd. LeMaitre Vascular Inc Livsmed Inc LuSeed Vascular Lymphatica Medtech SA MagniFeel Surgical Instruments Mayo Clinic Mecmaan Healthcare Ltd Medical University of South Carolina MediShield B.V. Medtronic Plc Mel Frontier Co Ltd Meta Biomed Co Ltd Michigan State University Naval Medical Research Center Next Science Ltd NorthShore University Health System NOvate Medical Technologies, LLC NoviRad Inc NovoGI LTD Novolock Ltd Novuson Surgical, Inc. Ohio State University Oklahoma State University Olympus America Inc OV World Co Ltd Pacira BioSciences Inc Parker Hannifin Corp Pavmed Inc PetVivo Holdings Inc Physcient, Inc. Polytechnic University of Catalonia Pro-Dex Inc Queen Mary University of London Ra Medical Systems Inc Ramona Optics Inc Ratner BioMedical Inc Resultados y Calidad del Sistema Sanitario Publico de Andalucia Rice University Saint Louis University Samyang Biopharmaceuticals Corp Sanovas Inc Shanghai MicroPort Medical Group Co Ltd Shanghai Shengzhe Medical Technology Co Ltd Shanghai Yichao Medical Equipment Co Ltd Silmag SA simedeq Simon Fraser University StatLink Surgical STRATA Skin Sciences Inc Stryker Corp SurgyAid, LLC Sutura Inc Teleflex Inc Tepha Inc The Feinstein Institute for Medical Research TransMed7 LLC Trinity College Dublin University of Auckland University of California University of California Davis University of California Los Angeles University of California San Diego University of Central Florida University of Chicago University of Maryland University of Maryland Baltimore University of Minnesota University of Missouri University of North Carolina University of South Florida University of Strasbourg University of Texas at Austin University of Texas Medical Branch at Galveston University of Toledo University of Utah University of Virginia US Medical Innovations LLC USGI Medical Inc Vanderbilt University Vascular Insights LLC VB Devices Vessi Medical Ltd Viveve Medical Inc Viveve, Inc. Wake Forest Baptist Medical Center Weill Cornell Medical College West Virginia University X-Biomedical Inc For more information about this report visit https://www.researchandmarkets.com/r/ekyrrp Source: GlobalData

100 项与 Institute for Medical Research, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Institute for Medical Research, Inc. 相关的转化医学

登录后查看更多信息